<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445195</url>
  </required_header>
  <id_info>
    <org_study_id>CS2514-2017-0003</org_study_id>
    <nct_id>NCT03445195</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entasis Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entasis Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and
      efficacy of IV ETX2514SUL in patients with complicated urinary tract infections (cUTIs) who
      are otherwise relatively healthy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and
      efficacy of IV ETX2514SUL in patients with cUTIs who are otherwise relatively healthy.
      Patients with Acute Pyelonephritis may also be enrolled. Approximately 80 patients will be
      randomized to receive either 1 g ETX2514/1 g sulbactam IV or matching placebo every 6 hours
      (q6h). All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Actual">May 17, 2018</completion_date>
  <primary_completion_date type="Actual">May 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of IV ETX2514SUL in patients with cUTIs.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Overall Success</measure>
    <time_frame>From baseline through day 21</time_frame>
    <description>The primary efficacy endpoint for this study was the proportion of patients with an overall success (clinical cure and micro-biologic eradication) for the m-MITT (Micro-biologically Modified Intent-to-Treat) Population at the TOC Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure</measure>
    <time_frame>Baseline to day 21</time_frame>
    <description>Proportion of patients with a response of clinical cure for the MITT(modified intent to treat), m-MITT (microbiologically modified intent to treat), CE(clinically evaluable), and ME(microbiologically evaluable) populations at the TOC(test of cure) visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic Eradication</measure>
    <time_frame>Baseline to day 21</time_frame>
    <description>Proportion of patients with a response of microbiologic eradication for the m-MITT(microbiologically modified intent to treat) and ME(microbiologically evaluable) populations at the TOC visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Imipenem/Cilastatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulbactam-ETX2514</intervention_name>
    <description>The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.</description>
    <arm_group_label>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</arm_group_label>
    <other_name>ETX2514SUL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching 1g IV solution.</description>
    <arm_group_label>Placebo + Imipenem/Cilastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem-cilastatin</intervention_name>
    <description>All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
    <arm_group_label>Placebo + Imipenem/Cilastatin</arm_group_label>
    <arm_group_label>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed informed consent form (ICF). If a study patient is unable to provide informed
             consent due to their medical condition, the patient's legally authorized
             representative may consent on behalf of the study patient as permitted by local law
             and institutional Standard Operating Procedures.

          -  Male or female, 18 to 90 years of age, inclusive.

          -  Expectation, in the judgment of the Investigator, that the patient's cUTI would
             require initial hospitalization and treatment with IV antibiotics.

          -  Documented or suspected cUTI or Acute pyelonephritis (AP).

        Exclusion Criteria:

          -  Gross hematuria requiring intervention other than administration of study drug or
             removal or exchange of a urinary catheter.

          -  Known non-renal source of infection such as endocarditis, osteomyelitis, abscess,
             meningitis, or pneumonia diagnosed within 7 days prior to randomization that would
             interfere with evaluation of response to the study antibiotics.

          -  Patient requires continuing treatment with probenecid, methotrexate, ganciclovir,
             valproic acid, or divalproex sodium during the study.

          -  Receipt of a single dose of a long-acting, potentially-effective systemic antibiotic
             with activity against Gram-negative uropathogens for more than 24 hours within the
             72-hour window prior to randomization.

          -  Requirement at time of randomization for any reason for additional systemic
             antimicrobial therapy (including antibacterial, antimycobacterial, or antifungal
             therapy) other than study drug, with the exception of a single oral dose of any
             antifungal treatment for vaginal candidiasis.

          -  Likely to require the use of an antibiotic for cUTI or AP prophylaxis during the
             patient's participation in the study [from randomization through the Late Follow-up
             (LFU) Visit].

          -  Any patients previously randomized in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anibal Calmaggi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medpace, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universeity Multiprofile Hospital for Active Teatment</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Teatment-Clinic of Nephrology</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Pirogov</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Teatment (MHAT) and Emergency Medicine - Doverie</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>February 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <results_first_submitted>May 14, 2019</results_first_submitted>
  <results_first_submitted_qc>May 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 5, 2019</results_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Sulbactam</mesh_term>
    <mesh_term>Cilastatin, Imipenem Drug Combination</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03445195/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT03445195/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</title>
          <description>Sulbactam-ETX2514: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Imipenem/Cilastatin</title>
          <description>Placebo: Matching 1g IV solution.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</title>
          <description>Sulbactam-ETX2514: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Imipenem/Cilastatin</title>
          <description>Placebo: Matching 1g IV solution.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.4" spread="17.55"/>
                    <measurement group_id="B2" value="54.9" spread="15.92"/>
                    <measurement group_id="B3" value="52.6" spread="17.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (Body Mass Index)</title>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.09" spread="6.661"/>
                    <measurement group_id="B2" value="28.63" spread="5.856"/>
                    <measurement group_id="B3" value="28.27" spread="6.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.6" spread="8.81"/>
                    <measurement group_id="B2" value="173.1" spread="8.44"/>
                    <measurement group_id="B3" value="172.8" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.79" spread="20.644"/>
                    <measurement group_id="B2" value="85.76" spread="17.929"/>
                    <measurement group_id="B3" value="84.45" spread="19.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening Creatinine Clearance</title>
          <units>Milliliters per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.3" spread="23.76"/>
                    <measurement group_id="B2" value="91.7" spread="18.19"/>
                    <measurement group_id="B3" value="93.4" spread="21.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Overall Success</title>
        <description>The primary efficacy endpoint for this study was the proportion of patients with an overall success (clinical cure and micro-biologic eradication) for the m-MITT (Micro-biologically Modified Intent-to-Treat) Population at the TOC Visit.</description>
        <time_frame>From baseline through day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</title>
            <description>Sulbactam-ETX2514: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Imipenem/Cilastatin</title>
            <description>Placebo: Matching 1g IV solution.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Success</title>
          <description>The primary efficacy endpoint for this study was the proportion of patients with an overall success (clinical cure and micro-biologic eradication) for the m-MITT (Micro-biologically Modified Intent-to-Treat) Population at the TOC Visit.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure</title>
        <description>Proportion of patients with a response of clinical cure for the MITT(modified intent to treat), m-MITT (microbiologically modified intent to treat), CE(clinically evaluable), and ME(microbiologically evaluable) populations at the TOC(test of cure) visit.</description>
        <time_frame>Baseline to day 21</time_frame>
        <population>The number analyzed for each population is different as the efficacy outcome is for the proportion of subjects with a clinical cure for each group.</population>
        <group_list>
          <group group_id="O1">
            <title>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</title>
            <description>Sulbactam-ETX2514: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Imipenem/Cilastatin</title>
            <description>Placebo: Matching 1g IV solution.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure</title>
          <description>Proportion of patients with a response of clinical cure for the MITT(modified intent to treat), m-MITT (microbiologically modified intent to treat), CE(clinically evaluable), and ME(microbiologically evaluable) populations at the TOC(test of cure) visit.</description>
          <population>The number analyzed for each population is different as the efficacy outcome is for the proportion of subjects with a clinical cure for each group.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MITT population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>m-MITT population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CE population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ME population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiologic Eradication</title>
        <description>Proportion of patients with a response of microbiologic eradication for the m-MITT(microbiologically modified intent to treat) and ME(microbiologically evaluable) populations at the TOC visit</description>
        <time_frame>Baseline to day 21</time_frame>
        <population>The analysis population differs for each group because the efficacy endpoint is for specific populations.</population>
        <group_list>
          <group group_id="O1">
            <title>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</title>
            <description>Sulbactam-ETX2514: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Imipenem/Cilastatin</title>
            <description>Placebo: Matching 1g IV solution.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiologic Eradication</title>
          <description>Proportion of patients with a response of microbiologic eradication for the m-MITT(microbiologically modified intent to treat) and ME(microbiologically evaluable) populations at the TOC visit</description>
          <population>The analysis population differs for each group because the efficacy endpoint is for specific populations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>m-MITT population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ME population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 hours to day 1, day 1, day 2, day 3, day 4, day 5, day 6,Day 7 to 14/ EOT + 1 day, 7 days post-EOT +/- 1 day(TOC), 7 days post-TOC +/- 2 days (LFU)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin</title>
          <description>Sulbactam-ETX2514: The ETX2514SUL regimen of 1 g ETX2514/1 g sulbactam infused over 3 hours q6h.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Imipenem/Cilastatin</title>
          <description>Placebo: Matching 1g IV solution.
Imipenem-cilastatin: All patients will receive background therapy with 500 mg IV imipenem/cilastatin q6h.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Entasis Therapeutics</organization>
      <phone>781-810-8940</phone>
      <email>Enquiries@entasistx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

